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Abstract
Background: Chronic kidney disease (CKD) is a significant and growing health burden globally. Tasmania has the highest
state prevalence for non-Indigenous Australians and it has consistently had the lowest incidence and prevalence of dialysis in
Australia.
Objective: To examine the gap between the high community prevalence of CKD in Tasmania and the low use of dialysis.
Methods: This is a retrospective cohort study using linked data from 5 health and 2 pathology data sets from the island state of
Tasmania, Australia. The study population consists of any person (all ages including children) who had a blood measurement of
creatinine with the included pathology providers between January 1, 2004, and December 31, 2017. This study population
(N=460,737) includes within it a CKD cohort, which was detected via pathology or documentation of kidney replacement therapy
(KRT; dialysis or kidney transplant). Kidney function (estimated glomerular filtration rate [eGFR]) was calculated using the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Individuals with 2 measures of eGFR<60 mL/min/1.73
m2, at least 90 days apart, were identified as having CKD and were included in the CKD cohort. Individuals treated with dialysis
or transplant were identified from the Australia and New Zealand Dialysis and Transplant Registry.
Results: The study population consisted of 460,737 people (n=245,573 [53.30%] female, mean age 47.4 years) who were
Tasmanian residents aged 18 years and older and were followed for a median of 7.8 years. During the later 5 years of the study
period, 86.79% (355,622/409,729) of Tasmanian adults were represented. The CKD cohort consisted of 56,438 people (ie, 12.25%
of the study population; 53.87% (30,405/56,438) female, mean age 69.9 years) followed for a median of 10.4 years with 56,039
detected via eGFR and 399 people detected via documentation of KRT. Approximately half (227,433/460,737, 49.36%) of the
study population and the majority of the CKD cohort (41,448/56,438, 73.44%) had an admission episode. Of the 55,366 deaths
recorded in the study population, 45.10% (24,970/55,366) had CKD.
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Conclusions: Whole-of-population approaches to examine CKD in the community can be achieved by data linkage. Over this
14-year period, CKD affected 12.25% (56,438/460,737) of Tasmanian adult residents and was present in 45.10% (24,970/55,366)
of deaths.
International Registered Report Identifier (IRRID): DERR1-10.2196/20160
(JMIR Res Protoc 2020;9(9):e20160) doi: 10.2196/20160
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Introduction
Chronic kidney disease (CKD) is a significant and growing
public health burden that manifests in substantial burden of
illness and premature mortality [1]. It has been named one of
the “most neglected chronic diseases” [2] and has a complex
interaction with other conditions, serving as a multiplier of risk
in all populations. CKD significantly increases the underlying
risk of premature death, hospitalization, cancer, diabetes, or
major vascular events by twofold to fivefold [2]. In 2012, the
total costs attributable to CKD in Australia were estimated at
AUD 4.1 billion (US $3 billion) [3]. Even early stage CKD is
associated with a 50% increase in health-related expenditure;
with later stages this is a sixfold increase [3]. Much of this cost
is associated with the use of kidney replacement therapy (KRT;
dialysis or kidney transplants).
Tasmania is the island state of Australia with a population of
half a million people spread over 68,000 km2. The whole of
Tasmania is classified as rural or remote with many people
(37%) living in areas of high disadvantage. The median age is
42 years, which is 5 years older than the median for Australia
[4]. A significant proportion of the Tasmanian population is
known to have CKD [5] with Tasmania having the highest state
prevalence of CKD (highest prevalence of estimated glomerular
filtration rate [eGFR] <60 mL/min/1.73 m2 and the highest
prevalence of albuminuria) [6] among non-Indigenous
Australians. Conversely, Tasmania has the lowest incidence of
uptake of dialysis and transplant (87 per million population
[pmp] compared with 124 pmp nationally) and the lowest
prevalence of dialysis (400 pmp compared with 536 pmp
nationally) [7,8]. Currently, the reasons for this gap between
high community prevalence of CKD and low use of dialysis
remain unknown. Dialysis use in all Australian states is funded
by the government and therefore decisions on its use are not
directly influenced by cost to the dialysis patient. Despite this
model, dialysis prevalence ranges from 2956 pmp in the
Northern Territory down to 400 pmp in Tasmania, likely
influenced by local population characteristics and treatment
pathways.
Linking routinely collected health data, pathology, and registry
data, we examine the gap between the high community
prevalence of CKD in Tasmania and the low use of dialysis.
We hypothesize that many Tasmanians with CKD will (1) have
a slow decline in kidney function (eGFR), (2) experience
multiple comorbidities, (3) have a higher mortality rate than
those without CKD, and (4) have limited access to tertiary health
services depending on their rurality and socioeconomic status.
Specific aims of this data linkage study are to (1) confirm the
Tasmanian burden of CKD; (2) identify geographic, gender,
and age-related variation in CKD burden, progression, and use
of dialysis; (3) report the mortality rate and survival of
Tasmanians with CKD; (4) examine how quickly kidney
function deteriorates; (5) report the general health burden of
Tasmanians with CKD including diabetes, hyperlipidemia,
cancer, and cardiovascular disease.
This will give us better quantitative information about the
detection and progression of CKD in Tasmanians, allowing us
to better understand this gap and identify health service and
community needs for better management of CKD in Tasmania.
Methods
Overview
This is a retrospective cohort study using linked data from 2
pathology providers and 5 administrative health data sets, from
January 1, 2004, to December 31, 2017, 14 years in total, in the
Australian state of Tasmania, an area of 68,400 km2 with
approximately 510,000 people [9].
Data Sets for Linkage
Ethical approval was granted by the Tasmanian Health and
Medical Human Research Ethics Committee (project H0016499,
approval date June 26, 2017) to access and link the following
data sets (Figure 1):
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Figure 1. Linkage map.
• Community and Hospital Pathology (Diagnostic Services
Pty Ltd [DSPL]): Hobart Pathology, Launceston Pathology,
and North-West Pathology. Pathology records provided
included date, eGFR, urinary albumin-to-creatinine ratio,
measures of diabetes (HbA1C), cholesterol, etc.
• Royal Hobart Hospital Pathology (RHHPATH): The largest
Tasmanian public hospital pathology service provider. The
data set includes pathology results for both community and
hospitalized Tasmanians. Pathology records provided are
the same as Community Pathology (above).
• Australia and New Zealand Dialysis and Transplant Registry
(ANZDATA): records on all Tasmanians treated with
dialysis or kidney transplant including the cause of kidney
disease and details of their dialysis or transplant.
• Public Hospital Admitted Patient data set: date, admission,
discharge, and clinical variables including primary and
related diagnoses by ICD-10 code (10th edition of
International Classification of Diseases and related health
problems) and classification by the Australian Refined
Diagnosis-Related Group for episode costing.
• Public Hospital Emergency Department Presentations: date,
episode, discharge, and clinical variables including
diagnoses and urgency-related groups for costing.
• Tasmanian Cancer Registry (TCR): clinical information
including date, type, and stage of cancer.
• Tasmanian Fact of Death (DEATH): date of death from
Births, Deaths and Marriages Tasmania; and Tasmanian
Cause of Death, which presents both coded underlying and
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contributing cause of death from the Australian
Coordinating Registry.
Study Population
This retrospective cohort study consists of an overall study
population cohort that includes within it a CKD cohort,
consisting of an eGFR cohort and a KRT cohort.
The study population consists of any adult (aged 18 years and
older) who had a blood measurement of creatinine with either
pathology provider, RHHPATH or DSPL, between January 1,
2004, and December 31, 2017. These providers provide the
majority of community pathology services to Southern,
Northern, North-West, and West of Tasmania and provide
inpatient pathology services to public and private hospitals in
both the south and north-west. We were unable to obtain
pathology results from Launceston General Hospital or smaller
Tasmanian private pathology providers. We then identified
people as being Tasmanian by comparing the recorded postcode
on pathology report at the date of creatinine measurement
against known Tasmanian Statistical Areas Level 2 (SA2).
The eGFR cohort is identified from within the study population,
where a patient has 2 recorded eGFR < 60 mL/min/1.73 m2, at
least 90 days apart [10], but no more than 3 years apart. We
then added to this people identified in the KRT cohort (below)
to comprise the CKD cohort.
The KRT cohort is identified from within the study population
using ANZDATA [7,8]. This registry was established in 1963
and maintains records of all patients with end-stage kidney
disease (ESKD) receiving dialysis or transplantation in Australia
and New Zealand. All patients residing in Tasmania receiving
ESKD treatment and recorded in ANZDATA between January
1, 2004, and December 31, 2017, who had blood creatinine
measured in the study period from the pathology providers
above, are included in the KRT cohort.
Data Linkage
All linkage was performed by the Tasmanian Data Linkage Unit
(TDLU), based at the Menzies Institute for Medical Research,
University of Tasmania. The TDLU utilizes probabilistic record
linkage using specialized data linkage software. This process
attempts to link pairs of records based on the probability of
them belonging to the same individual. The technique assigns
scores based upon the agreement or disagreement of various
linkage fields, and based upon the total score, record pairs are
classified as either matches or nonmatches. The matches are
recorded in the TDLU’s Master Linkage Map. A series of
Structured Query Language (SQL) queries are executed against
the Master Linkage Map to check for incorrect links (false
positives) and missed links (false negatives).
The TDLU uses a combination of linkage fields including source
system identifier; first name, middle name, and surname; date
of birth and date of death; gender; street address; suburb; and
postcode. Blocking strategies (only matched pairs that meet
certain basic criteria) are used to make the linkage process more
efficient. In order for two individuals to be compared, they must
have matching values for one or more blocking variables. The
TDLU currently blocks on surname, street address, date of birth,
derived postcode/month of birth variable. A process of
deduplication is applied to data sets prior to linkage. This
process identifies duplicate records within one data set using
specified linkage variables.
After linkage of 2 or more data sets is completed, a process of
clerical review is conducted. This ensures records that reach
the score threshold, and are linked, are true matches. Only those
pairs of records where there is at least one mismatch, based on
either first name, surname, date of birth, date of death, or sex,
between the newly linked record and the remaining records in
the group are reviewed. This is known as the review pool (pool).
The first stage of clerical review is to review all the groups in
the pool where the linkage system has combined 3 or more
groups of individuals (2 or more groups from the existing Master
Linkage Map and the new record being linked). This situation
occurs where there are 2 or more existing groups that are
potential matches for the new record. In the majority of cases,
the new record will become part of an existing group. There are
a small number of cases where the new record contains
information that allows 2 previously distinct groups to be
merged into 1 group.
The second stage of the clerical review process selects groups
from the pool where the new record has been linked with only
1 existing group from the Master Linkage Map. Groups are
reviewed based on the scores of the new record to other records
within the group. Groups with low scores are clerically reviewed
first to check for false positives. Reviewers then work upward
through the scores until no further false positives are identified.
Following this stage of review, a further round of quality
assurance is conducted to ensure the linked data satisfy a range
of logic checks. These checks aim to identify and correct false
positives (where 2 individuals have been incorrectly linked)
and false negatives (where records for the same individual have
not been linked).
On successful linkage, each individual identified was assigned
a project person identifier (PPID). There were 521,320 PPIDs
generated during data linkage (Table 1).
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Table 1. Linkage matrix: number of individuals identified in each data set.
DEATHSb,gTasmanian
Cancer
Registryf
Emergency
departmentb
Admitted patienteANZDATAb,dRHHc pathologybDSPLa
pathologyb
53,36441,764315,293237,1221098123,191490,026 hDSPL
pathologyb
26,17119,065125,038106,827835154,485123,191RHH
pathologyb
480184106099812148351098ANZDATAb
38,23430,535221,297253,036998106,827237,122Admitted
patiente
46,42231,062337,914221,2971060125,038315,293Emergency
departmentb
18,20942,46731,06230,53518419,06541,764Tasmanian
Cancer
Registryf
55,36618,20946,42238,23448026,17153,364DEATHSb
aDSPL: Diagnostic Services Pty Ltd.
bJanuary 1, 2004, to December 31, 2017.
cRHH: Royal Hobart Hospital.
dANZDATA: Australia and New Zealand Dialysis and Transplant Registry.
eJanuary 1, 2007, to December 31, 2017.
fJanuary 1, 2004, to December 31, 2016.
gDEATHS: Births, Deaths and Marriages Tasmania (Fact of Death).
hItalics indicate where data sets align.
Geocoding
The TDLU, in partnership with the Menzies Institute for Medical
Research, has developed a geocoding module to enable the
derivation of latitude and longitude for large unit record data
sets. The module uses fuzzy matching to link address data to
the Geocoded National Address File. After processing, the
system allocates a latitude and longitude at unit record level
based on the following geographic levels:
• Address: Records coded to the Address level have been
found as an exact match in the database and matched on
street number, street name, suburb, state, and postcode.
• Street: Records coded at the Street level have been matched
on street name and suburb, but the street number could not
be found. Records have been coded to the midpoint of the
street.
• Locality: Records coded at the Locality level have been
matched on suburb, state, and postcode only. Records have
been coded to the midpoint of the matching suburb.
• PO Box: These represent records geocoded to the Locality
of the PO Box address.
• None: These records relate to addresses that could not be
found in the database or Google Maps.
• Manual: These records have been found manually in Google
Maps through a clerical review module and had their
latitude and longitude recorded manually.
Once a latitude and longitude have been assigned, the system
assigns a meshblock (defined as a geographic area) code to
enable structures from the Australian Statistical Geography
Standard to be derived. Statistical areas ranging from SA1 to
SA4, as well as other Australian Bureau of Statistics geographic
structures, can be produced using this system. Given the small
population size and the potential for identification, we restricted
the coding to SA2 and above (population areas of >5000 people).
Data Cleaning
Access, cleaning, and analysis of the linked data set were limited
to 2 authors (AK and TS). In order to calculate eGFR from
serum creatinine (SCr) results, each PPID requires
documentation of gender (binary classification: male or female).
The PPID gender was accepted if it was recorded consistently
in each data set on every administrative record or if the majority
of data sets had gender recorded as a specific gender. The PPID
gender was left as unknown if it was recorded as unknown in
all available data sets or was ambiguous between administrative
data sets. If no gender could be determined, the pathology
records were removed from the data set. There were 357
individuals of the total PPIDs generated during data linkage
(521,320, 0.07%), with gender not recorded as male or female.
Detection of CKD via Pathology (eGFR Cohort)
SCr result was used to calculate eGFR using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation
[11,12]. Tasmanian laboratories use enzymatic assays for
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measurement of creatinine and all results are isotope dilution
mass spectrometry aligned as previously reported [13]. Stages
of CKD were classified based on first eGFR according to
National Kidney Foundation's Kidney Disease Outcomes Quality
Initiative (KDOQI) guidelines [10] and include stage 1
(eGFR≥90 mL/min/1.73 m2), stage 2 (eGFR=60-89
mL/min/1.73 m2), stage 3a (eGFR=45-59 mL/min/1.73 m2),
stage 3b (eGFR=30-44 mL/min/1.73 m2), stage 4 (eGFR=15-29
mL/min/1.73 m2), and stage 5 (eGFR<15 mL/min/1.73 m2 or
treated with dialysis or a transplant).
The following CKD-EPI formulae were used:
• For females with SCr ≤62 μmol/L: eGFR (mL/min/1.73
m2)=144×(SCr in μmol/L × 0.0113/0.7)–0.329× (0.993)age in
years
• For females with SCr >62 μmol/L: eGFR (mL/min/1.73
m2)=144 × (SCr in μmol/L × 0.0113/0.7) –1.209 × (0.993)age
in years
• For males with SCr ≤80 μmol/L: eGFR (mL/min/1.73
m2)=141 × (SCr in μmol/L × 0.0113/0.9)–0.411 × (0.993)age
in years
• For males with SCr >80 μmol/L: eGFR (mL/min/1.73
m2)=141 × (SCr in μmol/L × 0.0113/0.9)–1.209× (0.993)age
in years
The method to identify CKD consists of the following
(simplified) steps:
1. Calculation of eGFR (CKD-EPI) from SCr for each
pathology result in the study population.
2. Identification of CKD-qualifying eGFR results by filtering
to include only results where eGFR is <60 mL/min/1.73
m2
and PPID age at result ≥18 years.
3. Calculation of the number of days between qualifying eGFR
results (eGFR < 60 mL/min/1.73 m2 on at least two
occasions).
4. Search for a qualifying eGFR result date greater than 90
days since a previous qualifying result date, but no more
than 3 years since a previous qualifying result date.
5. If a second qualifying result date was detected between 90
days and 3 years, the date of the second qualifying result
was deemed to be date of diagnosis.
6. PPID was identified as Tasmanian if they had at least one
Tasmanian SA2 recorded in pathology.
There were 56,039 Tasmanian PPIDs diagnosed with CKD via
pathology.
Identifying CKD via ANZDATA Registry (KRT
Cohort)
Although all people treated with dialysis or transplant are
classified as having CKD, the pathology method described
above may not identify someone who has had a successful
kidney transplant and an eGFR >60 mL/min/m2. Therefore the
ANZDATA registry was checked for PPIDs that were not
detected via the pathology detection method and had at least
one treatment center within Tasmania or had received a
transplant.
There were 399 Tasmanian PPIDs detected via their presence
within the ANZDATA registry, due to one or more of the
following: (1) PPID entry being prior to start of the pathology
data set (ie, before January 1, 2004); (2) PPID having
insufficient pathology results within the pathology data set prior
to entry to ANZDATA; (3) PPID entry to ANZDATA prior to
age 18, and subsequently reaching the age of 18 in later years;
and (4) PPID had a transplant and a Tasmanian SA2 coded
pathology data after date of entry to ANZDATA.
CKD Cohort
We combined the PPIDs from both methods of detection to
create a CKD cohort. In addition to PPID and sex, the following
variables were extracted and added to the CKD cohort data set:
Age at detection, Date at detection, Date of pathology or Date
of entry to ANZDATA, Method of detection, eGFR CKD-EPI
at detection, CKD Stage at detection, and SA2 at detection.
For the PPIDs that were present in ANZDATA, the following
additional variables were added: Age at entry to registry, Date
of entry to registry, eGFR CKD-EPI at entry to registry, Date
of first dialysis, Age at first dialysis, Date of first transplant (if
applicable), and Age at first transplant (if applicable)
Pathology Variables Obtained
In addition to creatinine, we obtained 25 other pathology
variables (Multimedia Appendix 1). If PPIDs had an SCr test
during the study period, we received all requested pathology
data for them, regardless of if they had an SCr test on the same
day or not.
Identifying Cause of CKD and Comorbidities
The cause of CKD was identified (where available) from the
admitted patient data set using ICD-10 codes (Multimedia
Appendix 2) and ANZDATA using primary renal disease code.
Comorbidities of interest were identified using ICD-10AM
codes for diabetes (ICD-10AM codes E10-14), cardiovascular
disease (ICD-10AM codes I00-99), and cancer (ICD-10AM
codes C00-D48). Other comorbidities were determined using
both the Charlson Comorbidity Index [14] and Elixhauser
Comorbidity Index [15].
Identifying Cause of Death
Death data are recorded in multiple data sets including DEATH,
TCR, Admitted Patient, and ANZDATA. DEATH (fact of death)
was used as the primary data source, with additional death dates
and cause of death added from additional data sets. Specific
kidney disease–related cause of death was identified using the
Australian Institute of Health and Welfare report, “Deaths from
Chronic Kidney Disease” [16].
Results
Study Population
The linkage identified 521,320 people who had an SCr test in
Tasmania during the 14-year study period, of whom 460,737
were determined to be Tasmanian residents (at the time of
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pathology test) aged 18 years or older and therefore became the
study population.
For the 5-year period (2013-2017) there were 355,622 unique
individuals aged 18 years and older included in our linked data
set. As the estimated adult resident population in Tasmania was
409,729 at this time, we estimate that our study population
represents approximately 86.79% of Tasmania’s resident adult
population during this 5-year period (Table 2).
The study population showed significant variation by age
(Figure 2A and 2B), with the older population (aged 60 years
and older) more likely to have a pathology test in this 5-year
period (P<.001).
There were 460,737 people in the study population, of which
53.30% (245,573/460,737) were female with a mean age of
47.4 (SD 18.3) years, having 1.1 creatinine results per person
per year over the 7.8 (interquartile range [IQR] 8.3) years of
follow-up (Table 3).
Table 2. The number of unique individuals and proportion of Tasmania’s adult population included in the data set in the previous 1, 2, 3, or 5 years
(% of estimated resident population [9] aged 18 years and older [ERPa 18+]).
Unique PPID % of ERPPopulation
(ERP 18+b)
Unique PPIDa
5 years3 years2 years1 year5 years3 years2 years1 yearYear
27.1727.1727.1727.17365,59799,33899,33899,33899,3382004
42.6742.6742.6729.57369,271157,570157,570157,570109,1842005
53.7753.7745.3431.33372,707200,422200,422168,977116,7842006
62.8056.6947.9433.68376,512236,465213,435180,495126,8032007
70.7559.8251.3236.92381,317269,775228,096195,704140,7922008
73.4562.7054.2138.76386,739284,069242,501209,638149,9002009
75.7765.1856.2140.50391,666296,769255,302220,167158,6452010
78.4967.7558.7842.82395,228310,200267,756232,304169,2352011
81.1870.1461.0644.44396,592321,985278,154242,159176,2432012
83.4772.2862.8646.11397,807332,048287,543250,054183,4402013
84.8673.2563.5945.75399,987339,409292,988254,351182,9942014
85.7573.5163.2345.76402,512345,153295,896254,519184,1732015
86.4873.7663.7346.75405,167350,375298,855258,280189,4092016
86.7974.2164.7147.62409,729355,622304,058265,153195,1142017
aERP: estimated resident population.
bPPID: project person identifier.
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Figure 2. (a) Male unique PPIDs by age group per year (% of Tasmanian Population). (b) Female unique PPIDs by age group per year (% of Tasmanian
Population).
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Table 3. Study demographics.a
ANZDATAcPathologyCKDb cohortStudy populationDemographics
39956,03956,438460,737Number of individuals (18
years and older)
51.2 (15.5)69.9 (11.7)69.7 (11.8)47.4 (18.3)Age (years) at initial
eGFRd, mean (SD)
150/399 (37.59)30,267/56,039 (54.01)30,405/56,438 (53.87)245,573/460,737 (53.30)Female, n/N (%)
9.2 (9.8)10.4 (6.2)10.4 (6.2)7.8 (8.3)Follow-up (years), median
(IQR)
9.9 (10.6)2.4 (2.8)2.4 (2.8)1.1 (2)Creatinine tests per person
per year, median (IQR)
64.9 (12.5)83 (9.5)82.8 (9.7)77.4 (13.9)Age (years) at death, mean
(SD)
19324,77724,97055,366Number of deaths
318 (79.70)41,130 (73.40)41,448 (73.44)227,433 (49.36)PPIDe (%) with an admis-
sion
68,718387,619456,3371,319,293Total number of admis-
sions
88.8 (79.3)1.9 (24.2)3.4 (46.8)0.9 (4.1)Admissions per person per
year, median (IQR)
360 (90.23)44,441 (79.30)44,801 (79.38)295,943 (64.23)PPID (%) with emergency
department presentation
3260258,343261,6031,470,819Total number of emergen-
cy department presenta-
tions
1.7 (2)0.9 (1.3)0.9 (1.3)0.9 (1.5)Emergency department
presentations per person
per year, median (IQR)
69 (17.29)12,906 (23.03)12,975 (22.99)42,099 (9.14)PPID (%) with cancer
33.7 (28.8)57.1 (22.9)56.6 (23.2)83.9 (29.4)eGFR (mL/min/1.73 m2),
mean (SD)
50.4 (131.4)25.5 (91.6)26.4 (93.6)13.4 (77)uACRf (mg/mmol), mean
(SD)
aAdmissions include same day and overnight.
bCKD: chronic kidney disease.
cANZDATA: Australia and New Zealand Dialysis and Transplant Registry.
deGFR: estimated glomerular filtration rate.
ePPID: project person identifier.
fuACR: urinary albumin-to-creatinine ratio.
CKD Cohort
The CKD cohort consisted of 56,438 people, of which 53.87%
(30,405/56,438) were female with a mean age of 69.7 (SD 11.8)
years and median follow-up of 10.4 (IQR 6.2) years. Stage of
CKD (when first meeting the criteria for CKD in the data set)
was stage 3a in 73.07% (41,242/56,438), stage 3b in 20.05%
(11,315/56,438), stage 4 in 5.21% (2938/56,438), and stage 5
or on KRT in 1.67% (943/56,438).
KRT Cohort
The KRT cohort consisted of 399 people, of which there were
37.6% (150/399) of female with a mean age of 51.2 (SD 15.5)
years. Follow-up of the KRT cohort was for a median of 9.2
(IQR 9.8) years.
Admissions and Comorbidities
Of the 460,737 people in the study population, 227,233 (49.32%)
were in the Admitted Patient data set for a median of 1.0 (IQR
4.6) admissions per year. Of the 56,437 people in the CKD
cohort, 41,448 (73.44%) were in the admitted data set for a
median of 3.4 (IQR 46.8) admissions per year (Table 3),
including same-day admissions for dialysis.
Deaths
During the 14-year study period there were 55,366 Tasmanian
deaths recorded, of which 24,970 (45.10%) were in our CKD
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cohort. Mean age of death in our CKD cohort was 84.1 (SD
9.6) years for women and 81.3 (SD 9.6) years for men.
Discussion
Overview of the Protocol
The aim of this study was to take a whole-of-population
approach to identify and follow (through data linkage)
Australians who develop CKD, and identify important outcomes
such as hospital admission, dialysis use, kidney transplantation,
cancer, or death. We identified 460,737 individuals who had a
Tasmanian residential postcode recorded at the time of
pathology collection and were aged 18 years and over. Of these,
56,438 (12.25%) met the KDIGO (Kidney Disease: Improving
Global Outcomes) definition of CKD [10], making this the
largest Australian CKD cohort yet reported.
The strengths of this data linkage project are the
whole-of-population approach (an estimated 86.79%
[355,622/409,729] of resident adult population included),
longitudinal nature allowing adequate follow-up (median
follow-up of CKD cohort of 10.4 years), and a relatively
contained island population with a low population turnover [9].
In addition, we use biochemical measures rather than self-report
to determine prevalence of CKD, diabetes, and hyperlipidemia
and link to legislated data sets including the Births, Deaths and
Marriages Tasmania Fact of death and the TCR. Our estimates
of CKD prevalence are consistent with our previously published
2007 data [5] and the Australian Health Survey [6].
The quality and completeness of the administrative data sets
included were variable, but data conflicts and missingness were
proportionally small (no sex recorded for 0.07% [357/521,320]
of PPIDs generated during data linkage). While ethnicity was
recorded in several data sets, concordance was <90% and further
work needs to be done to improve recognition and recording of
diversity within these administrative data sets.
Notable limitations of our study include the lack of primary
health data, prescribed medications including secondary
prevention strategies, general information on health risk factors
including actual weight, BMI, smoking history, or blood
pressure control. In addition, we rely on coding practices across
public health institutions for comorbidities. Private hospital
admission data were not included, nor were admissions of
Tasmanian residents who travel to other jurisdictions for
management of these chronic conditions.
Throughout this study we have used KDIGO definitions of CKD
stating that a person with 2 measurements of eGFR <60
mL/min/1.73 m2 90 days apart has CKD. This definition does
not separate kidney disease from kidney aging and therefore
does not take into account the call for age-specific thresholds
to allow for an age-adapted definition [17].
We have commenced the analysis of this linked data set and
hope to report our findings to the Tasmanian community within
12 months. The results will give us better quantitative
information about detection and progression of CKD in
Tasmanians, areas and populations of high disease prevalence,
and risk factors for CKD. This will allow us to better understand
this gap and identify health service and community needs, to
optimize management of CKD in Tasmania through early
detection and treatment.
Conclusions
We have described our methodology for the largest
(retrospective) Australian CKD cohort reported to date. We will
use these linked data to estimate the burden of CKD in the
Tasmanian community, the progression of CKD to ESKD, the
presence and influence of coexisting comorbidities and
important outcomes including use of KRT (dialysis or
transplant), episodes of cancer, hospitalizations, and death. We
will use these data to better understand the apparent gap between
high community prevalence of CKD and low use of KRT.
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Multimedia Appendix 2
ICD-10AM codes used to identify the cause of CKD.
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